Research programme: bladder diseases therapeutics - TARIS Biomedical/AstraZeneca

Drug Profile

Research programme: bladder diseases therapeutics - TARIS Biomedical/AstraZeneca

Alternative Names: TAR-302; TD-210

Latest Information Update: 31 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca; TARIS Biomedical
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bladder cancer; Overactive bladder

Most Recent Events

  • 16 Oct 2013 Preclinical trials in Overactive bladder in USA (Intravesicular) after October 2013 (TARIS pipeline, December 2013)
  • 16 Oct 2013 Preclinical trials in Bladder cancer in USA (Intravesicular)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top